GlaxoSmithKline, under activist pressure, gets some relief as Elliott won't push for sale or slash R&D: report

Investors have been eyeing a potential shakeup at GlaxoSmithKline ever since Elliott Management took a large stake in the company last month. After concerns of a potential sale emerged last week, it appears the activist investor aims to take a more conservative tack.